SRPT vs ACAD โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
SRPT Captures Institutional Edge (3โ1 Pillars ยท 2โ8 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Sarepta Therapeutics,, Inc. Common Stock (SRPT) driven by superior Valuation, Momentum & Technical, Options & Structure while ACAD counters with relative strength in Growth & Margin. Fundamentally, SRPT trades at 10.8x Forward P/E with -0.4% operating margin (-4.5% YoY revenue) versus ACAD at 17.8x Forward P/E and 10.2% operating margin (+22.8% YoY). In options structure, SRPT sits in BREAKDOWN (7th %ile IV; Dealer Gamma Walls on Pro) against ACAD sits in BREAKDOWN (4th %ile IV; Dealer Gamma Walls on Pro).
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | SRPT Revenue | ACAD Revenue | SRPT Op. Margin | ACAD Op. Margin | Margin Edge |
|---|---|---|---|---|---|
| FY2018 | $300M | $220M | -114.1% | -110.6% | ACAD |
| FY2019 | $380M | $340M | -185.3% | -72.7% | ACAD |
| FY2020 | $460M | $440M | -123.8% | -64.9% | ACAD |
| FY2021 | $610M | $480M | -75.1% | -35.2% | ACAD |
| FY2022 | $840M | $520M | -63.5% | -43.2% | ACAD |
| FY2023 | $1.14B | $730M | -23.4% | -10.1% | ACAD |
| FY2024 | $1.79B | $960M | 12.2% | 24.1% | ACAD |
| FY2025 | $1.86B | $1.07B | -37.5% | 9.8% | ACAD |
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | SRPT | ACAD | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $1.7B | $3.1B | Larger Scale | ACAD |
| Trailing P/E Ratio Valuation | N/M | 8.6x | Lower Multiple | ACAD |
| Forward P/E Ratio Valuation | 10.8x | 17.8x | Lower Multiple | SRPT |
| Revenue Growth (YoY) Growth | -4.5% | +22.8% | Higher Growth | ACAD |
| Operating Margin (TTM) Profitability | -0.4% | 10.2% | Higher Margin | ACAD |
| Net Profit Margin Profitability | -5.9% | 30.1% | Higher Margin | ACAD |
| Return on Equity (ROE) Capital Efficiency | -8.1% | 31.4% | Higher ROE | ACAD |
| 52-Week Range Position Momentum | 5% ($15โ$25) | 21% ($16โ$31) | Stronger Trend | ACAD |
| Beta / 30D Volatility Risk Regime | 1.47ฮฒ ยท 58% Vol | 0.11ฮฒ ยท 93% Vol | Lower Realized Risk | SRPT |
| Unified Institutional Score Composite Signal | 37.8 / 100 (SELL) | 42.0 / 100 (HOLD) | Higher Composite | ACAD |